{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:39:36Z","timestamp":1790959176683,"version":"4.1.0"},"reference-count":111,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T00:00:00Z","timestamp":1720656000000},"content-version":"am","delay-in-days":314,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.drudis.2023.103689","type":"journal-article","created":{"date-parts":[[2023,6,28]],"date-time":"2023-06-28T02:33:17Z","timestamp":1687919597000},"page":"103689","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Update on the treatment of cancer cachexia"],"prefix":"10.1016","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0171-0218","authenticated-orcid":false,"given":"Kenichi","family":"Nishie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomomi","family":"Nishie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiichi","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Hanaoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2023.103689_b0005","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/nrclinonc.2012.209","article-title":"Understanding the mechanisms and treatment options in cancer cachexia","volume":"10","author":"Fearon","year":"2013","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.drudis.2023.103689_b0010","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S1470-2045(10)70218-7","article-title":"Definition and classification of cancer cachexia: an international consensus","volume":"12","author":"Fearon","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.drudis.2023.103689_b0015","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s13539-012-0087-1","article-title":"Cancer cachexia: impact, mechanisms and emerging treatments","volume":"4","author":"Vaughan","year":"2013","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.drudis.2023.103689_b0020","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1016\/j.clnu.2016.12.003","article-title":"Association between cachexia, chemotherapy and outcomes in older cancer patients: a systematic review","volume":"36","author":"Caillet","year":"2017","journal-title":"Clin Nutr"},{"key":"10.1016\/j.drudis.2023.103689_b0025","doi-asserted-by":"crossref","first-page":"e200","DOI":"10.1038\/oncsis.2016.3","article-title":"Understanding cachexia as a cancer metabolism syndrome","volume":"5","author":"Porporato","year":"2016","journal-title":"Oncogenesis"},{"key":"10.1016\/j.drudis.2023.103689_b0030","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.cmet.2012.06.011","article-title":"Cancer cachexia: mediators, signaling, and metabolic pathways","volume":"16","author":"Fearon","year":"2012","journal-title":"Cell Metab"},{"key":"10.1016\/j.drudis.2023.103689_b0035","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/jcsm.12402","article-title":"Orphan disease status of cancer cachexia in the USA and in the European Union: a systematic review","volume":"10","author":"Anker","year":"2019","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.drudis.2023.103689_b0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100092","article-title":"Cancer cachexia in adult patients: ESMO Clinical Practice Guidelines","volume":"6","author":"Arends","year":"2021","journal-title":"ESMO Open"},{"key":"10.1016\/j.drudis.2023.103689_b0045","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/s12276-022-00752-w","article-title":"Understanding the molecular basis of anorexia and tissue wasting in cancer cachexia","volume":"54","author":"Yeom","year":"2022","journal-title":"Exp Mol Med"},{"key":"10.1016\/j.drudis.2023.103689_b0050","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/35086018","article-title":"Ghrelin: an orexigenic and somatotrophic signal from the stomach","volume":"2","author":"Inui","year":"2001","journal-title":"Nat Rev Neurosci"},{"key":"10.1016\/j.drudis.2023.103689_b0055","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s13539-014-0142-1","article-title":"Psychosocial impact of cancer cachexia","volume":"5","author":"Hopkinson","year":"2014","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.drudis.2023.103689_b0060","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.clnu.2009.12.004","article-title":"Consensus definition of sarcopenia, cachexia and pre-cachexia: joint document elaborated by Special Interest Groups (SIG) \u201ccachexia-anorexia in chronic wasting diseases\u201d and \u201cnutrition in geriatrics\u201d","volume":"29","author":"Muscaritoli","year":"2010","journal-title":"Clin Nutr"},{"key":"10.1016\/j.drudis.2023.103689_b0065","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.jgo.2017.08.013","article-title":"Pearls of optimizing nutrition and physical performance of older adults undergoing cancer therapy","volume":"8","author":"Vigano","year":"2017","journal-title":"J Geriatr Oncol"},{"key":"10.1016\/j.drudis.2023.103689_b0070","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.clnu.2008.06.013","article-title":"Cachexia: a new definition","volume":"27","author":"Evans","year":"2008","journal-title":"Clin Nutr"},{"key":"10.1016\/j.drudis.2023.103689_b0075","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1093\/ajcn\/83.6.1345","article-title":"Definition of cancer cachexia: effect of weight loss, reduced food intake, and systemic inflammation on functional status and prognosis","volume":"83","author":"Fearon","year":"2006","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.drudis.2023.103689_b0080","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1177\/0148607108325076","article-title":"Defining and classifying cancer cachexia: a proposal by the SCRINIO Working Group","volume":"33","author":"Bozzetti","year":"2009","journal-title":"JPEN J Parenter Enteral Nutr"},{"key":"10.1016\/j.drudis.2023.103689_b0085","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.clnu.2016.09.004","article-title":"ESPEN guidelines on definitions and terminology of clinical nutrition","volume":"36","author":"Cederholm","year":"2017","journal-title":"Clin Nutr"},{"key":"10.1016\/j.drudis.2023.103689_b0090","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1200\/JCO.20.00611","article-title":"Management of cancer cachexia: ASCO Guideline","volume":"38","author":"Roeland","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.drudis.2023.103689_b0095","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.clnu.2012.01.011","article-title":"Inflammation in cancer cachexia: to resolve or not to resolve (is that the question?)","volume":"31","author":"Seelaender","year":"2012","journal-title":"Clin Nutr"},{"key":"10.1016\/j.drudis.2023.103689_b0100","doi-asserted-by":"crossref","first-page":"17105","DOI":"10.1038\/nrdp.2017.105","article-title":"Cancer-associated cachexia","volume":"4","author":"Baracos","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.drudis.2023.103689_b0105","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.1200\/JCO.1995.13.10.2600","article-title":"Increased resting energy expenditure and weight loss are related to a systemic inflammatory response in lung cancer patients","volume":"13","author":"Staal-van den Brekel","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.drudis.2023.103689_b0110","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1038\/bjc.1993.126","article-title":"Increased protein degradation and decreased protein synthesis in skeletal muscle during cancer cachexia","volume":"67","author":"Smith","year":"1993","journal-title":"Br J Cancer"},{"key":"10.1016\/j.drudis.2023.103689_b0115","first-page":"E996","article-title":"Activation of the ATP-ubiquitin-proteasome pathway in skeletal muscle of cachectic rats bearing a hepatoma","volume":"268","author":"Baracos","year":"1995","journal-title":"Am J Physiol"},{"key":"10.1016\/j.drudis.2023.103689_b0120","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.cmet.2007.09.009","article-title":"The E3 Ligase MuRF1 degrades myosin heavy chain protein in dexamethasone-treated skeletal muscle","volume":"6","author":"Clarke","year":"2007","journal-title":"Cell Metab"},{"key":"10.1016\/j.drudis.2023.103689_b0125","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/s41586-023-06047-y","article-title":"EDA2R-NIK signalling promotes muscle atrophy linked to cancer cachexia","volume":"617","author":"Bilgic","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2023.103689_b0130","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1002\/iub.1392","article-title":"Myostatin: expanding horizons","volume":"67","author":"Sharma","year":"2015","journal-title":"IUBMB Life"},{"key":"10.1016\/j.drudis.2023.103689_b0135","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1210\/en.2006-1500","article-title":"Ectopic expression of myostatin induces atrophy of adult skeletal muscle by decreasing muscle gene expression","volume":"148","author":"Durieux","year":"2007","journal-title":"Endocrinology"},{"key":"10.1016\/j.drudis.2023.103689_b0140","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1038\/nrd3278","article-title":"Muscle disorders: preventing wastage","volume":"9","author":"Tse","year":"2010","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2023.103689_b0145","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/nrd4467","article-title":"Muscle wasting in disease: molecular mechanisms and promising therapies","volume":"14","author":"Cohen","year":"2015","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2023.103689_b0150","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1089\/ars.2020.8041","article-title":"The redox balance: a target for interventions against muscle wasting in cancer cachexia?","volume":"33","author":"Penna","year":"2020","journal-title":"Antioxid Redox Signal"},{"key":"10.1016\/j.drudis.2023.103689_b0155","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1038\/s41571-023-00734-5","article-title":"Cancer-associated cachexia - understanding the tumour macroenvironment and microenvironment to improve management","volume":"20","author":"Argiles","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.drudis.2023.103689_b0160","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.semcdb.2015.10.039","article-title":"Lipolytic and thermogenic depletion of adipose tissue in cancer cachexia","volume":"54","author":"Tsoli","year":"2016","journal-title":"Semin Cell Dev Biol"},{"key":"10.1016\/j.drudis.2023.103689_b0165","doi-asserted-by":"crossref","first-page":"5531","DOI":"10.1158\/0008-5472.CAN-06-4585","article-title":"Mechanism of increased lipolysis in cancer cachexia","volume":"67","author":"Agustsson","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.drudis.2023.103689_b0170","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/cdd.2016.113","article-title":"Hedgehog signaling in bone regulates whole-body energy metabolism through a bone-adipose endocrine relay mediated by PTHrP and adiponectin","volume":"24","author":"Zhang","year":"2017","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.drudis.2023.103689_b0175","doi-asserted-by":"crossref","first-page":"298","DOI":"10.3389\/fonc.2020.00298","article-title":"Management of cancer cachexia: attempting to develop new pharmacological agents for new effective therapeutic options","volume":"10","author":"Marceca","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.drudis.2023.103689_b0180","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41574-018-0123-0","article-title":"Inter-tissue communication in cancer cachexia","volume":"15","author":"Argiles","year":"2018","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.drudis.2023.103689_b0185","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1016\/j.biocel.2013.07.016","article-title":"Control of food intake and muscle wasting in cachexia","volume":"45","author":"Amitani","year":"2013","journal-title":"Int J Biochem Cell Biol"},{"key":"10.1016\/j.drudis.2023.103689_b0190","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.cytogfr.2021.11.002","article-title":"Pathophysiological role of growth differentiation factor 15 (GDF15) in obesity, cancer, and cachexia","volume":"64","author":"Siddiqui","year":"2022","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1016\/j.drudis.2023.103689_b0195","doi-asserted-by":"crossref","first-page":"80","DOI":"10.21037\/apm.2018.11.01","article-title":"Prokinetics and ghrelin for the management of cancer cachexia syndrome","volume":"8","author":"Malik","year":"2019","journal-title":"Ann Palliat Med"},{"key":"10.1016\/j.drudis.2023.103689_b0200","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1002\/jcb.26174","article-title":"Tumor necrosis factor-alpha: role in development of insulin resistance and pathogenesis of type 2 diabetes mellitus","volume":"119","author":"Akash","year":"2018","journal-title":"J Cell Biochem"},{"key":"10.1016\/j.drudis.2023.103689_b0205","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s13539-010-0011-5","article-title":"Ghrelin for cachexia","volume":"1","author":"Akamizu","year":"2010","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.drudis.2023.103689_b0210","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2022.960341","article-title":"Cancer cachexia as a multiorgan failure: reconstruction of the crime scene","volume":"10","author":"Ferrara","year":"2022","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.drudis.2023.103689_b0215","doi-asserted-by":"crossref","first-page":"e108687","DOI":"10.1371\/journal.pone.0108687","article-title":"Nutritional advice in older patients at risk of malnutrition during treatment for chemotherapy: a two-year randomized controlled trial","volume":"9","author":"Bourdel-Marchasson","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.drudis.2023.103689_b0220","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1093\/annonc\/mdy114","article-title":"Systematic review and meta-analysis of the evidence for oral nutritional intervention on nutritional and clinical outcomes during chemo(radio)therapy: current evidence and guidance for design of future trials","volume":"29","author":"de van der Schueren","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.drudis.2023.103689_b0225","article-title":"Exercise for cancer cachexia in adults","volume":"3","author":"Grande","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.drudis.2023.103689_b0230","doi-asserted-by":"crossref","first-page":"e290","DOI":"10.3747\/co.24.3619","article-title":"Exercise for people with cancer: a systematic review","volume":"24","author":"Segal","year":"2017","journal-title":"Curr Oncol"},{"key":"10.1016\/j.drudis.2023.103689_b0235","first-page":"4827","article-title":"Mechanism of inhibition of a tumor lipid-mobilizing factor by eicosapentaenoic acid","volume":"58","author":"Price","year":"1998","journal-title":"Cancer Res"},{"key":"10.1016\/j.drudis.2023.103689_b0240","doi-asserted-by":"crossref","unstructured":"Dewey A, Baughan C, Dean T, Higgins B, Johnson I. Eicosapentaenoic acid (EPA, an omega-3 fatty acid from fish oils) for the treatment of cancer cachexia. Cochrane Database Syst Rev. 2007;2007(1):CD004597. https:\/\/doi.org\/10.1002\/14651858.CD004597.pub2.","DOI":"10.1002\/14651858.CD004597.pub2"},{"key":"10.1016\/j.drudis.2023.103689_b0245","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1080\/01635581.2015.976315","article-title":"The consumption of omega-3 polyunsaturated fatty acids improves clinical outcomes and prognosis in pancreatic cancer patients: a systematic evaluation","volume":"67","author":"Ma","year":"2015","journal-title":"Nutr Cancer"},{"key":"10.1016\/j.drudis.2023.103689_b0250","doi-asserted-by":"crossref","first-page":"223","DOI":"10.3109\/10408369309084669","article-title":"Protein and amino acid metabolism in cancer cachexia: investigative techniques and therapeutic interventions","volume":"30","author":"Pisters","year":"1993","journal-title":"Crit Rev Clin Lab Sci"},{"key":"10.1016\/j.drudis.2023.103689_b0255","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/1475-2891-11-52","article-title":"L-Carnitine-supplementation in advanced pancreatic cancer (CARPAN)\u2013a randomized multicentre trial","volume":"11","author":"Kraft","year":"2012","journal-title":"Nutr J"},{"key":"10.1016\/j.drudis.2023.103689_b0260","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/jcsm.12127","article-title":"A systematic review on the role of vitamins, minerals, proteins, and other supplements for the treatment of cachexia in cancer: a European Palliative Care Research Centre cachexia project","volume":"8","author":"Mochamat","year":"2017","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.drudis.2023.103689_b0265","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.critrevonc.2013.07.015","article-title":"Clinical evaluation and optimal management of cancer cachexia","volume":"88","author":"Tuca","year":"2013","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.drudis.2023.103689_b0270","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1200\/JCO.1993.11.1.152","article-title":"Body-composition changes in patients who gain weight while receiving megestrol acetate","volume":"11","author":"Loprinzi","year":"1993","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.drudis.2023.103689_b0275","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1002\/cncr.22924","article-title":"Association between megestrol acetate treatment and symptomatic adrenal insufficiency with hypogonadism in male patients with cancer","volume":"110","author":"Dev","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.drudis.2023.103689_b0280","doi-asserted-by":"crossref","unstructured":"Ruiz Garcia V, Lopez-Briz E, Carbonell Sanchis R, Gonzalvez Perales JL, Bort-Marti S. Megestrol acetate for treatment of anorexia-cachexia syndrome. Cochrane Database Syst Rev. 2013;2013(3):CD004310. https:\/\/doi.org\/10.1002\/14651858.CD004310.pub3.","DOI":"10.1002\/14651858.CD004310.pub3"},{"key":"10.1016\/j.drudis.2023.103689_b0285","doi-asserted-by":"crossref","first-page":"3756","DOI":"10.3390\/jcm11133756","article-title":"A systematic review and meta-analysis of the clinical use of megestrol acetate for cancer-related anorexia\/cachexia","volume":"11","author":"Lim","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.drudis.2023.103689_b0290","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.ygyno.2011.12.435","article-title":"A randomized phase III clinical trial of a combined treatment for cachexia in patients with gynecological cancers: evaluating the impact on metabolic and inflammatory profiles and quality of life","volume":"124","author":"Maccio","year":"2012","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.drudis.2023.103689_b0295","doi-asserted-by":"crossref","first-page":"8500","DOI":"10.1200\/JCO.2005.01.8010","article-title":"Systematic review of the treatment of cancer-associated anorexia and weight loss","volume":"23","author":"Yavuzsen","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.drudis.2023.103689_b0300","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.annonc.2020.02.016","article-title":"Cancer-related fatigue: ESMO Clinical Practice Guidelines for diagnosis and treatment","volume":"31","author":"Fabi","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.drudis.2023.103689_b0305","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1002\/cncr.22944","article-title":"A placebo-controlled double blind trial of etanercept for the cancer anorexia\/weight loss syndrome: results from N00C1 from the North Central Cancer Treatment Group","volume":"110","author":"Jatoi","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.drudis.2023.103689_b0310","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.lungcan.2009.06.020","article-title":"A placebo-controlled, double-blind trial of infliximab for cancer-associated weight loss in elderly and\/or poor performance non-small cell lung cancer patients (N01C9)","volume":"68","author":"Jatoi","year":"2010","journal-title":"Lung Cancer"},{"key":"10.1016\/j.drudis.2023.103689_b0315","doi-asserted-by":"crossref","first-page":"60","DOI":"10.4103\/2277-9175.179182","article-title":"Pentoxifylline treatment in patients with cancer cachexia: a double-blind, randomized, placebo-controlled clinical trial","volume":"5","author":"Mehrzad","year":"2016","journal-title":"Adv Biomed Res"},{"key":"10.1016\/j.drudis.2023.103689_b0320","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1136\/gut.2004.047563","article-title":"Thalidomide in the treatment of cancer cachexia: a randomised placebo controlled trial","volume":"54","author":"Gordon","year":"2005","journal-title":"Gut"},{"key":"10.1016\/j.drudis.2023.103689_b0325","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/rco2.54","article-title":"Lenalidomide in cancer cachexia: a randomized trial of an anticancer drug applied for anti-cachexia","volume":"5","author":"Blum","year":"2022","journal-title":"JCSM Rapid Commun"},{"key":"10.1016\/j.drudis.2023.103689_b0330","article-title":"Thalidomide for managing cancer cachexia","volume":"2012(4):CD008664","author":"Reid","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.drudis.2023.103689_b0335","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/hed.20662","article-title":"Results of a pilot study of the effects of celecoxib on cancer cachexia in patients with cancer of the head, neck, and gastrointestinal tract","volume":"30","author":"Lai","year":"2008","journal-title":"Head Neck"},{"key":"10.1016\/j.drudis.2023.103689_b0340","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s00109-009-0547-z","article-title":"Phase II nonrandomized study of the efficacy and safety of COX-2 inhibitor celecoxib on patients with cancer cachexia","volume":"88","author":"Mantovani","year":"2010","journal-title":"J Mol Med (Berl)"},{"key":"10.1016\/j.drudis.2023.103689_b0345","first-page":"2479","article-title":"Randomized double-blind clinical trial of combined treatment with megestrol acetate plus celecoxib versus megestrol acetate alone in cachexia-anorexia syndrome induced by GI cancers","volume":"26","author":"Kouchaki","year":"2018","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.drudis.2023.103689_b0350","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3109\/0284186X.2012.724536","article-title":"Non-steroidal anti-inflammatory treatment in cancer cachexia: a systematic literature review","volume":"52","author":"Solheim","year":"2013","journal-title":"Acta Oncol"},{"key":"10.1016\/j.drudis.2023.103689_b0355","doi-asserted-by":"crossref","first-page":"4785","DOI":"10.1002\/cncr.27430","article-title":"Effects of ghrelin administration during chemotherapy with advanced esophageal cancer patients: a prospective, randomized, placebo-controlled phase 2 study","volume":"118","author":"Hiura","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.drudis.2023.103689_b0360","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1097\/SPC.0000000000000012","article-title":"Clinical development of ghrelin axis-derived molecules for cancer cachexia treatment","volume":"7","author":"Ali","year":"2013","journal-title":"Curr Opin Support Palliat Care"},{"key":"10.1016\/j.drudis.2023.103689_b0365","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S1470-2045(15)00558-6","article-title":"Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials","volume":"17","author":"Temel","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.drudis.2023.103689_b0370","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1093\/annonc\/mdx192","article-title":"ROMANA 3: a phase 3 safety extension study of anamorelin in advanced non-small-cell lung cancer (NSCLC) patients with cachexia","volume":"28","author":"Currow","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.drudis.2023.103689_b0375","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.lungcan.2017.07.023","article-title":"Anamorelin for advanced non-small-cell lung cancer with cachexia: systematic review and meta-analysis","volume":"112","author":"Nishie","year":"2017","journal-title":"Lung Cancer"},{"key":"10.1016\/j.drudis.2023.103689_b0380","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1002\/cncr.31128","article-title":"Anamorelin (ONO-7643) for the treatment of patients with non-small cell lung cancer and cachexia: results from a randomized, double-blind, placebo-controlled, multicenter study of Japanese patients (ONO-7643-04)","volume":"124","author":"Katakami","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.drudis.2023.103689_b0385","doi-asserted-by":"crossref","first-page":"4294","DOI":"10.1002\/cncr.32406","article-title":"A multicenter, open-label, single-arm study of anamorelin (ONO-7643) in advanced gastrointestinal cancer patients with cancer cachexia","volume":"125","author":"Hamauchi","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.drudis.2023.103689_b0390","unstructured":"https:\/\/www.haigan.gr.jp\/guideline\/2022\/. The Japan Cancer Society, Lung Cancer Treatment Guidelines, 2022, Accessed May 30, 2023."},{"key":"10.1016\/j.drudis.2023.103689_b0395","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1002\/jcsm.13191","article-title":"Pilot clinical trial of macimorelin to assess safety and efficacy in patients with cancer cachexia","volume":"14","author":"Herodes","year":"2023","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.drudis.2023.103689_b0400","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM199607043350101","article-title":"The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men","volume":"335","author":"Bhasin","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2023.103689_b0405","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1002\/jcsm.12295","article-title":"A randomized trial of adjunct testosterone for cancer-related muscle loss in men and women","volume":"9","author":"Wright","year":"2018","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.drudis.2023.103689_b0410","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s11912-016-0522-0","article-title":"Study design and rationale for the Phase 3 Clinical Development Program of Enobosarm, a selective androgen receptor modulator, for the prevention and treatment of muscle wasting in cancer patients (POWER Trials)","volume":"18","author":"Crawford","year":"2016","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.drudis.2023.103689_b0415","first-page":"951","article-title":"Treatment of cancer-related anorexia with olanzapine and megestrol acetate: a randomized trial","volume":"18","author":"Navari","year":"2010","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.drudis.2023.103689_b0420","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1001\/jamaoncol.2020.1052","article-title":"Olanzapine for the treatment of advanced cancer-related chronic nausea and\/or vomiting: a randomized pilot trial","volume":"6","author":"Navari","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.drudis.2023.103689_b0425","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1200\/JCO.22.01997","article-title":"Randomized double-blind placebo-controlled study of olanzapine for chemotherapy-related anorexia in patients with locally advanced or metastatic gastric, hepatopancreaticobiliary, and lung cancer","volume":"41","author":"Sandhya","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.drudis.2023.103689_b0430","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1177\/1049909109345685","article-title":"Phase II trial of mirtazapine for cancer-related cachexia and anorexia","volume":"27","author":"Riechelmann","year":"2010","journal-title":"Am J Hosp Palliat Care"},{"key":"10.1016\/j.drudis.2023.103689_b0435","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/j.jpainsymman.2021.05.017","article-title":"Mirtazapine in cancer-associated anorexia and cachexia: a double-blind placebo-controlled randomized trial","volume":"62","author":"Hunter","year":"2021","journal-title":"J Pain Symptom Manage"},{"key":"10.1016\/j.drudis.2023.103689_b0440","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1002\/1097-0142(19900615)65:12<2657::AID-CNCR2820651210>3.0.CO;2-S","article-title":"A controlled trial of cyproheptadine in cancer patients with anorexia and\/or cachexia","volume":"65","author":"Kardinal","year":"1990","journal-title":"Cancer"},{"key":"10.1016\/j.drudis.2023.103689_b0445","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1200\/JCO.2002.20.2.567","article-title":"Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment Group study","volume":"20","author":"Jatoi","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.drudis.2023.103689_b0450","first-page":"3029","article-title":"The effect of nabilone on appetite, nutritional status, and quality of life in lung cancer patients: a randomized, double-blind clinical trial","volume":"26","author":"Turcott","year":"2018","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.drudis.2023.103689_b0455","doi-asserted-by":"crossref","unstructured":"Bar-Sela G, Zalman D, Semenysty V, Ballan E. The effects of dosage-controlled cannabis capsules on cancer-related cachexia and anorexia syndrome in advanced cancer patients: pilot study. Integr Cancer Ther. 2019;18:1534735419881498. https:\/\/doi.org\/10.1177\/1534735419881498.","DOI":"10.1177\/1534735419881498"},{"key":"10.1016\/j.drudis.2023.103689_b0460","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1200\/JCO.1994.12.6.1126","article-title":"Placebo-controlled trial of hydrazine sulfate in patients with newly diagnosed non-small-cell lung cancer","volume":"12","author":"Loprinzi","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.drudis.2023.103689_b0465","doi-asserted-by":"crossref","first-page":"877","DOI":"10.7326\/0003-4819-133-11-200012050-00011","article-title":"Fatal hepatorenal failure associated with hydrazine sulfate","volume":"133","author":"Hainer","year":"2000","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.drudis.2023.103689_b0470","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/S0885-3924(00)00138-X","article-title":"A double-blind, crossover study of controlled-release metoclopramide and placebo for the chronic nausea and dyspepsia of advanced cancer","volume":"19","author":"Bruera","year":"2000","journal-title":"J Pain Symptom Manage"},{"key":"10.1016\/j.drudis.2023.103689_b0475","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1002\/jcsm.12126","article-title":"Espindolol for the treatment and prevention of cachexia in patients with stage III\/IV non-small cell lung cancer or colorectal cancer: a randomized, double-blind, placebo-controlled, international multicentre phase II study (the ACT-ONE trial)","volume":"7","author":"Stewart Coats","year":"2016","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.drudis.2023.103689_b0480","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1016\/0959-8049(96)00136-0","article-title":"Is there a role for melatonin in the treatment of neoplastic cachexia?","volume":"32A","author":"Lissoni","year":"1996","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.drudis.2023.103689_b0485","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1200\/JCO.2012.43.6766","article-title":"Effects of melatonin on appetite and other symptoms in patients with advanced cancer and cachexia: a double-blind placebo-controlled trial","volume":"31","author":"Del Fabbro","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.drudis.2023.103689_b0490","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s10637-015-0226-6","article-title":"Xilonix, a novel true human antibody targeting the inflammatory cytokine interleukin-1 alpha, in non-small cell lung cancer","volume":"33","author":"Hong","year":"2015","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.drudis.2023.103689_b0495","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/S1470-2045(17)30006-2","article-title":"MABp1 as a novel antibody treatment for advanced colorectal cancer: a randomised, double-blind, placebo-controlled, phase 3 study","volume":"18","author":"Hickish","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.drudis.2023.103689_b0500","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s13045-017-0417-z","article-title":"Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial","volume":"10","author":"Verstovsek","year":"2017","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.drudis.2023.103689_b0505","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1002\/jcsm.12331","article-title":"LY2495655, an antimyostatin antibody, in pancreatic cancer: a randomized, phase 2 trial","volume":"9","author":"Golan","year":"2018","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.drudis.2023.103689_b0510","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1517\/14712598.2011.627850","article-title":"A humanized anti-IL-6 antibody (ALD518) in non-small cell lung cancer","volume":"11","author":"Bayliss","year":"2011","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.drudis.2023.103689_b0515","unstructured":"Pharmaceuticals N, Novartis. Clinical study of BYM338 for the treatment of unintentional weight loss in patients with cancer of the lung or the pancreas. https:\/\/ClinicalTrials.gov\/show\/NCT01433263. 2011."},{"key":"10.1016\/j.drudis.2023.103689_b0520","doi-asserted-by":"crossref","first-page":"5458","DOI":"10.1158\/1078-0432.CCR-19-1065","article-title":"First-in-human phase I study of the activin A inhibitor, STM 434, in patients with granulosa cell ovarian cancer and other advanced solid tumors","volume":"25","author":"Tao","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.drudis.2023.103689_b0525","doi-asserted-by":"crossref","first-page":"5425619","DOI":"10.1155\/2022\/5425619","article-title":"Efficacy of curcumin on treating cancer anorexia-cachexia syndrome in locally or advanced head and neck cancer: a double-blind, placebo-controlled randomised phase IIa trial (CurChexia)","volume":"2022","author":"Thambamroong","year":"2022","journal-title":"J Nutr Metab"},{"key":"10.1016\/j.drudis.2023.103689_b0530","doi-asserted-by":"crossref","first-page":"6855","DOI":"10.1158\/1078-0432.CCR-04-0373","article-title":"Effects of recombinant erythropoietin in palliative treatment of unselected cancer patients","volume":"10","author":"Lindholm","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.drudis.2023.103689_b0535","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.clnu.2011.10.005","article-title":"Randomized phase III clinical trial of a combined treatment with carnitine + celecoxib \u00b1 megestrol acetate for patients with cancer-related anorexia\/cachexia syndrome","volume":"31","author":"Madeddu","year":"2012","journal-title":"Clin Nutr"},{"key":"10.1016\/j.drudis.2023.103689_b0540","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1002\/jcsm.12201","article-title":"A randomized phase II feasibility trial of a multimodal intervention for the management of cachexia in lung and pancreatic cancer","volume":"8","author":"Solheim","year":"2017","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.drudis.2023.103689_b0545","doi-asserted-by":"crossref","first-page":"3637","DOI":"10.1016\/j.clnu.2020.04.008","article-title":"Effect of a leucine-rich supplement in combination with nutrition and physical exercise in advanced cancer patients: a randomized controlled intervention trial","volume":"39","author":"Storck","year":"2020","journal-title":"Clin Nutr"},{"key":"10.1016\/j.drudis.2023.103689_b0550","doi-asserted-by":"crossref","unstructured":"Wang YF, An ZY, Lin DH, Jin WL. Targeting cancer cachexia: molecular mechanisms and clinical study. MedComm (2020). 2022;3(4):e164. https:\/\/doi.org\/10.1002\/mco2.164.","DOI":"10.1002\/mco2.164"},{"key":"10.1016\/j.drudis.2023.103689_b0555","first-page":"1075","article-title":"Web questionnaire survey on appetite loss and weight loss associated with cancer cachexia Japanese evidence for patients of cancer cachexia(J-EPOCC)-the understanding of cancer cachexia","volume":"47","author":"Morimoto","year":"2020","journal-title":"Gan To Kagaku Ryoho"}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644623002052?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644623002052?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T13:07:12Z","timestamp":1761224832000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644623002052"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":111,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["S1359644623002052"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2023.103689","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Update on the treatment of cancer cachexia","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2023.103689","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103689"}}